Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
What similarly acting projects are still unpartnered?
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.